SEC Filing Summary: Greatbatch, Inc. (Form 8-K)
Business Context and Reporting Period
This Current Report on Form 8-K, dated April 28, 2007, discloses that Greatbatch, Inc. ("Greatbatch") has entered into a definitive agreement to acquire Enpath Medical, Inc. ("Enpath"). The transaction is structured as a tender offer followed by a merger, with Greatbatch's indirect subsidiary, Chestnut Acquisition Corporation, acting as the purchaser. The filing was signed on April 30, 2007.
Key Financial Metrics and Transaction Terms
- Acquisition Price: $14.38 per share of Enpath common stock, payable in cash without interest.
- Termination Fee: Enpath may be required to pay a termination fee of $3 million under specific circumstances, such as accepting an alternative proposal or changing its board recommendation.
- Top-Up Option: Greatbatch holds an option to purchase additional shares to reach 90% ownership, capped at 19.9% of shares outstanding as of April 28, 2007, or the amount requiring shareholder approval.
- Financial Statements: This filing does not contain revenue, profit, cash flow, margin, debt, or liquidity metrics for Greatbatch or Enpath.
Material Changes and Conditions
The primary material change is the entry into the Merger Agreement and a Tender and Support Agreement. Completion of the transaction is subject to several conditions:
- Tendered shares must constitute a majority of Enpath's outstanding shares on a fully-diluted basis.
- No laws or orders prohibiting the transaction.
- Expiration or termination of the Hart-Scott-Rodino Antitrust waiting period.
- Unanimous approval by the boards of directors of both Greatbatch and Enpath has been obtained.
Outlook, Risks, and Management Commentary
Management expects to commence the tender offer promptly and consummate the merger as soon as possible thereafter. The transaction is intended to complement and advance Greatbatch's business, with expectations regarding earnings per share, operating margins, and sales growth detailed in forward-looking statements.
Risks and Contingencies:
- The acquisition may not be completed or may be delayed if tender offer conditions are not met.
- Expected financial and strategic benefits may not be realized in a timely manner or at all.
- Forward-looking statements are subject to uncertainties and risks beyond Greatbatch's control.
Key Facts for Investor Verification
- Verify the final tender offer statement and solicitation/recommendation statement filed with the SEC for detailed terms.
- Confirm whether the 90% ownership threshold is met to determine if a short-form merger (without shareholder vote) is possible.
- Monitor the status of the Hart-Scott-Rodino Antitrust waiting period.
- Review the "Risk Factors" sections in the most recent Form 10-K filings for both Greatbatch and Enpath.
- Note that the filing text does not provide specific financial performance data (revenue, profit, cash flow) for either company.